Key Points
- Wall Street strategists say the AI rally is not a bubble, but signs of an “air pocket” reflect cooling sentiment and stretched expectations.
- Slowing enterprise AI adoption and uneven earnings contributions are prompting analysts to reevaluate near-term growth assumptions.
- Investors are watching whether capital expenditures, chip demand, and monetization metrics can sustain the next phase of AI-driven market performance.
As AI stocks continue to dominate global equity markets, several leading strategists are warning that the sector may be entering what they call an “air pocket” — a temporary slowdown rather than a structural reversal. While valuations remain elevated, analysts argue that the current phase reflects a normalization in expectations rather than the formation of a bubble. For institutional investors in Israel and worldwide, this shift signals the need to reexamine assumptions about AI monetization, earnings visibility, and the trajectory of technology-led market gains.
Wall Street strategists see cooling momentum, not collapsing fundamentals
Several investment banks report that enthusiasm surrounding AI infrastructure, chips, and cloud services has begun to moderate. The sector’s meteoric rise in 2023–2025 was driven by explosive growth in GPU demand and aggressive capital spending by hyperscalers. But with deployment timetables stretching and corporate budgets tightening, analysts say the market is entering a more balanced phase.
Strategists describe this slowdown as an “air pocket” — a moment when revenue acceleration pauses yet underlying fundamentals remain intact. This perspective contrasts with bubble warnings that surfaced earlier in the year. Despite slowing indicators, earnings reports from leading AI firms show resilient margins, strong backlog pipelines, and sustained spending on next-generation compute infrastructure. The takeaway: growth is still coming, but perhaps not at the breakneck pace markets had priced in.
Valuation pressures emerge as earnings timelines lengthen
Part of the reset stems from valuations that remain historically high. The multiples for key AI beneficiaries — from semiconductor manufacturers to cloud platforms — expanded rapidly amid optimism about generative AI adoption. Now, analysts are pressing companies for clearer guidance on when these investments will convert into recurring revenue and measurable productivity gains.
For example, while demand for AI accelerators remains robust, some hyperscale customers are slowing orders to evaluate utilization rates and refine deployment strategies. Enterprise adoption, particularly outside the technology sector, has proven slower and more cost-sensitive than early projections suggested. This disconnect is prompting equity research desks to adjust models, emphasizing sustainable revenue ramps rather than hypergrowth narratives.
Investment implications for tech-heavy portfolios
For portfolio managers, the current reassessment may drive greater differentiation across AI-related equities. Companies with clear monetization pathways, strong hardware supply chains, and proven customer adoption cycles may outperform those relying solely on long-term hype. Meanwhile, firms exposed to cloud infrastructure and high-performance compute remain well positioned as multi-year AI investments continue across the private and public sectors.
Israeli institutional investors — many of whom hold substantial positions in global semiconductors, cybersecurity, and cloud software — are closely monitoring the shift. The “air pocket” narrative is viewed not as a warning signal but as a reminder that the AI cycle will unfold in stages, with earnings progression serving as the ultimate driver of valuations.
Looking ahead, investors will focus on upcoming earnings from major AI chipmakers, cloud providers, and enterprise software firms. Key indicators include capex commitments, GPU supply-demand balance, AI revenue disclosure practices, and early productivity data from enterprise implementations. If fundamentals remain strong, Wall Street expects the next phase of AI growth to be steadier, more measurable, and potentially more durable than the initial surge — marking a reset rather than a reversal in the global AI narrative.
Comparison, examination, and analysis between investment houses
Leave your details, and an expert from our team will get back to you as soon as possible
* This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.
To read more about the full disclaimer, click here- Ronny Mor
- •
- 7 Min Read
- •
- ago 4 seconds
SKN | Will Big Tech’s AI Race Trigger a $100 Billion Funding Wave in 2026?
The world’s largest technology companies may be heading into a historic year of capital raising as the financial demands of
- ago 4 seconds
- •
- 7 Min Read
The world’s largest technology companies may be heading into a historic year of capital raising as the financial demands of
- Ronny Mor
- •
- 6 Min Read
- •
- ago 52 seconds
SKN | Larry Fink Softens Crypto Stance as BlackRock’s Bitcoin ETF Becomes the Largest in the U.S.
BlackRock CEO Larry Fink has taken his most supportive public stance yet on cryptocurrency, signaling a major evolution in
- ago 52 seconds
- •
- 6 Min Read
BlackRock CEO Larry Fink has taken his most supportive public stance yet on cryptocurrency, signaling a major evolution in
- sagi habasov
- •
- 8 Min Read
- •
- ago 35 minutes
SKN | Will Citadel’s New AI Assistant Redefine How Equity Investors Research and Analyze Markets?
Citadel has introduced a sophisticated artificial intelligence research assistant aimed at transforming how its investment teams analyze equities, marking one
- ago 35 minutes
- •
- 8 Min Read
Citadel has introduced a sophisticated artificial intelligence research assistant aimed at transforming how its investment teams analyze equities, marking one
- Lior mor
- •
- 7 Min Read
- •
- ago 2 hours
SKN | Will Novo Nordisk’s Ozempic Launch Reshape India’s Fast-Growing Obesity and Diabetes Market?
Novo Nordisk is moving toward a December launch of its blockbuster diabetes treatment Ozempic in India, according to multiple sources
- ago 2 hours
- •
- 7 Min Read
Novo Nordisk is moving toward a December launch of its blockbuster diabetes treatment Ozempic in India, according to multiple sources